Bidirectional pharmacodynamic interaction between pegylated liposomal CKD-602 (S-CKD602) and monocytes in patients with refractory solid tumors

References

• Anonymous. (2004). ABI 007. Drugs R D 5:155–159.
   PubMedGoogle Scholar
• Allen, T. M., Martin, F. J. (2004). Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 31:5–15.
   PubMed Web of Science ®Google Scholar
• Allen, T. M., Stuart, D. D. (2005). Liposomal pharmacokinetics: classical, sterically stabilized, cationic liposomes and immunoliposomes. In: Janoff, A. S. (Ed.), Liposomes: rational design. New York: Marcel Dekker.
   Google Scholar
• Chelvarajan, R. L., Collins, S. M., van Willigen, J. M., Bondada, S. (2005). The unresponsiveness of aged mice to polysaccharide antigens is a result of a defect in macrophage function. J Leukoc Biol 77:503–512.
   PubMed Web of Science ®Google Scholar
• Crul, M. (2003). CKD-602. Curr Opin Invest Drugs 4:1455–1459.
   PubMedGoogle Scholar
• Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51:691–743.
   PubMed Web of Science ®Google Scholar
• Gelmon, K., Hirte, H., Fisher, B., Walsh, W., Ptaszynski, M., Hamilton, M., et al. (2004). A phase I study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every 3 weeks in patients with solid cancers. Invest New Drugs 22:263–275.
   PubMed Web of Science ®Google Scholar
• Giles, F. J., Tallman, M. S., Garcia-Manero, G., Cortes, J. E., Thomas, D. A., Wierda, W. G., et al. (2004). Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer 100:1449–1458.
   PubMed Web of Science ®Google Scholar
• Lee, D. H., Kim, S. W., Suh, C., Lee, J. S., Lee, J. H., Lee, S. J., et al. (2007). Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Ann Oncol 19:123–127.
   PubMedGoogle Scholar
• Lee, H.-P., Seo, S.-S., Ryu, S.-Y., Kim, J.-H., Bang, Y.-J., Park, S.-Y., et al. (2008). Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer. Gynecol Oncol 109:359–363.
   PubMed Web of Science ®Google Scholar
• Lee, J. H., Lee, J. M., Lim, K. H., Kim, J. K., Ahn, S. K., Bang, Y. J., et al. (2000). Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative. Ann N Y Acad Sci 922:324–325.
   PubMed Web of Science ®Google Scholar
• Loercher, A. E., Nash, M. A., Kavanagh, J. J., Platsoucas, C. D., Freedman, R. S. (1999). Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 163:6251–6260.
   PubMed Web of Science ®Google Scholar
• Melichar, B., Savary, C. A., Patenia, R., Templin, S., Melicharova, K., Freedman, R. S. (2003). Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma. Int J Gynecol Cancer 13:435–443.
   PubMedGoogle Scholar
• Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., et al. (1991). Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 88:11460–11464.
   PubMed Web of Science ®Google Scholar
• Park, J. W., Benz, C. C., Martin, F. J. (2004). Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31:196–205.
   PubMed Web of Science ®Google Scholar
• Plowden, J., Renshaw-Hoelscher, M., Engleman, C., Katz, J., Sambhara, S. (2004). Innate immunity in aging: impact on macrophage function. Aging Cell 3:161–167.
   PubMed Web of Science ®Google Scholar
• Sidone, B., Edwards, R., Zamboni, B., Strychor, S., Maruca, L., Zamboni, W. (2007). Evaluation of body surface area (BSA) based dosing, age, and body composition as factors affecting the pharmacokinetic (PK) variability of STEALTH liposomal doxorubicin (Doxil). AACR Meeting Abstracts C107.
   Google Scholar
• Yu, N. Y., Conway, C., Pena, R. L., Chen, J. Y. (2007). STEALTH liposomal CKD-602, a topoisomerase I inhibitor, improves the therapeutic index in human tumor xenograft models. Anticancer Res 27:2541–2545.
   PubMed Web of Science ®Google Scholar
• Yu, N. Y., Conway, C. A., Pena, R. L. S. (2005). Improvement in therapeutic index by STEALTH(R) CKD-602 vs. free CKD-602 and topotecan in human tumor xenografts. AACR Meeting Abstracts 562.
   Google Scholar
• Zamboni, W. C. (2005) Liposomal, nanoparticle, and conjugated formulations of anticancer agents. Clin Cancer Res 11:8230–8234.
   PubMed Web of Science ®Google Scholar
• Zamboni, W. C., Edwards, R. P., Mountz, J. M., Eiseman, J. L., Basse, P.H., Zamboni, B. A., et al. (2007a). The development of liposomal and nanoparticle anticancer agents: methods to evaluate the encapsulated and released drug in plasma and tumor and phenotypic probes for pharmacokinetic (PK) and pharmacodynamic (PD) disposition. Proceedings of the 2007 NSTI Nanotechnology Conference (#1582) and Trade Show, Santa Clara, California, USA, May 20–24, 2007. Available at: www.nsti.org. Accessed on June 9, 2010.
   Google Scholar
• Zamboni, W. C., Eiseman, J. L., Strychor, S., Rice, P., Joseph, E., Potter, D. M., et al. (2006). Relationship between the plasma and tumor disposition of STEALTH(R) liposomal CKD-602 (S-CKD602) and macrophages/dendritic cells (MDC) in mice bearing human tumor xenografts. AACR Meeting Abstracts 1280–1281.
   Google Scholar
• Zamboni, W. C., Maruca, L., Strychor, S. (2007b). Age and body composition related effects on the pharmacokinetic disposition of STEALH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors. 2007 ASCO Annual Meeting Proceedings, Part I. J Clin Oncol 25:2528.
   PubMedGoogle Scholar
• Zamboni, W. C., Ramalingam, S., Friedland, D. M., Edwards, R. P., Stoller, R. G., Strychor, S., et al. (2009). Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin Cancer Res 15:1466–1472.
   PubMed Web of Science ®Google Scholar
• Zamboni, W. C., Strychor, S., Joseph, E., Walsh, D. R., Zamboni, B. A., Parise, R. A., et al. (2007c). Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts. Clin Cancer Res 13:7217–7223.
   PubMed Web of Science ®Google Scholar